Introduction: Kilovoltge cone beam computed tomography (kV-CBCT) allows for tumor localization and response assessment during definitive chemoradiotherapy for locally advanced NSCLC. We hypothesize that significant tumor volume loss occurs early during radiotherapy and that the extent of volume loss correlates with clinical outcomes.
Introduction
There are an estimated 222,500 new cases of and 157,000 deaths related to lung cancer annually in the United States. 1 NSCLC accounts for 80% of all lung cancers, and 30% to 40% of these patients present with locally advanced disease. Most patients with locally advanced NSCLC are not amenable to surgical resection on account of medical comorbidities, poor underlying lung function, poor tumor resectability, and/or extensive mediastinal lymphadenopathy. The standard of care for locally advanced unresectable NSCLC in patients with good performance status is definitive chemoradiation to doses of 60 to 66 Gy in 1.8-to 2.0-Gy fractions concurrent with carboplatin/paclitaxel or cisplatin/etoposide. 2, 3 Despite advances in radiation technology, outcomes remain poor, with median overall survival (OS) of 20 to 28 months, 5-year OS rates of 10% to 20%, and locoregional failure rates of 35% to 70%. [4] [5] [6] The meta-analysis of phase III data concerning locally advanced NSCLC performed by Auperin et al. reported a correlation between locoregional control (LRC) and OS outcomes, suggesting that strategies to improve LRC have the potential to improve survival outcomes. 7 Although radiation dose escalation had been pursued in the recent past, results from RTOG 0617, a prospective randomized phase III study comparing 60 Gy and 74 Gy of radiotherapy in locally advanced NSCLC, demonstrated that benefit from simple dose escalation may not outweigh added toxicity and that escalating dose to a uniform volume may not provide benefit. One strategy to improve outcomes is to utilize adaptive radiotherapy, the practice of adjusting radiotherapy plans on the basis of reduced tumor volume changes during treatment. Implementation of adaptive radiotherapy has become more practical with the widespread use of fast computers and conformable registration software to facilitate rapid replanning. 8 Theoretical advantages of adaptive planning include smaller overall treatment volumes and more normal tissue sparing, suggesting an opportunity for safer dose escalation efforts.
Adaptive planning requires a clear understanding of tumor volume dynamics during therapy, including the timing and magnitude of volume changes. Its clinical utility relies on early tumor shrinkage during treatment, as clinically significant dosimetric advantages depend on our ability to shrink treatment volumes away from doselimiting normal tissues. Onboard kilovoltage cone beam computed tomography (kV-CBCT) image guidance has become more widely available in recent years and may serve as a convenient tool to evaluate tumor volume dynamics. The goals of this study are to utilize kV-CBCT to evaluate primary tumor volume dynamics during treatment and to investigate the prognostic value of absolute and relative tumor volume changes seen during treatment.
Methods and Materials

Patient Selection
Between June 2012 and February 2016, 65 patients with locally advanced, biopsy-proven, unresectable stage III NSCLC treated with definitive chemoradiation in our department were identified and analyzed in this institutional review board-approved retrospective study. All patients received radiotherapy on linear accelerators (Varian Truebeam [Varian Medical Systems, Palo Alto, CA]) equipped with kV-CBCT onboard imaging. During radiotherapy, kV-CBCT imaging was utilized for verification of patient setup. kV-CBCT images were imported to the Eclipse treatment planning system (Varian). Primary tumors were recontoured, and gross tumor volumes (GTVs) (in cm 3 ) were calculated. A total of 13 patients with poor imaging quality or unreliable primary GTV contours on account of anatomy and/or atelectasis were eliminated from the cohort, leaving 53 evaluable patients. Clinical data collection included age, sex, smoking status, performance status, pathology report findings, clinical stage, radiotherapy, and chemotherapy treatment information, as well as sites and timing of lung cancer recurrence and OS.
Radiotherapy Details
All patients were treated in the supine position with definitive, conventionally fractionated thoracic radiotherapy using three-dimensional conformal, intensitymodulated radiation therapy, or volumetric-modulated arc therapy techniques. Radiotherapy targets were delineated using a four-dimensional planning computed tomography (CT) simulation in treatment position fused with the staging fludeoxyglucose F 18 positron emission tomography (PET) scan. The gross primary tumor volume and gross nodal volume were delineated in lung and mediastinal window settings, respectively. The fourdimensional planning chest CT was then used to expand each GTV to internal target volumes (ITVs) (primary ITV and nodal ITV) to account for respiratory motion on the CT average scan. Each ITV was then expanded by 6 to 10 mm to create clinical target volumes (CTVs) (primary CTV and nodal CTV) to cover potential microscopic disease. The CTVs were adapted to exclude bony and vascular normal structures. Primary CTV and nodal CTV were then expanded by 5 to 8 mm to create planning target volumes (PTVs) (primary PTV and nodal PTV). The PTVs were then combined to create a total PTV structure, to which dose was prescribed. Elective nodal irradiation was not delivered.
Patient Follow-up
After they competed definitive chemoradiation with or without consolidative chemotherapy, patients routinely were followed up with medical oncology and radiation oncology care. Interval history and physical and CT scans of the chest, with contrast unless contraindicated, were performed every 3 to 6 months for 3 years, then every 6 months for 2 years, and then annually thereafter.
CBCT Imaging and Contouring
kV-CBCT images taken before fraction 1 (F1), fraction 11 (F11), fraction 21 (F21), and the final fraction (F final ) were coregistered with the planning CT scan and used to contour the GTV at each time point. These contours were generated manually by a single radiation oncologist by utilizing lung window levels for each scan and then reviewed by an independent radiation oncologist. Only primary tumors were contoured and evaluated, as gross nodal volumes were difficult to visualize on CBCT images.
Statistical Analysis
GTV volumes were calculated for each patient at each of the four time points described earlier. Absolute and relative volume changes were calculated at each time point. Each absolute and relative volume change parameter was dichotomized according to the median value for the group. Univariate Cox regression methods were used to determine whether adapted GTV volume changes correlated with LRC, distant metastasis-free survival (DMFS), progression-free survival (PFS), and OS. LRC, DMFS, PFS, and OS curves were generated by the Kaplan-Meier method. We then performed a multivariate analysis (MVA) using Cox proportions hazards model to validate the results discovered by univariate analysis (UVA). Covariates for MVA included age, sex, smoking history (pack-years), concurrent chemotherapy regimen (cisplatin/etoposide versus carboplatin/paclitaxel), initial primary tumor volume (cm 
Results
Patient Characteristics
The median follow-up for the cohort was 19.3 months (range 1.6-35.0). There were 27 females and 25 males. The median age at diagnosis was 64. Biopsy samples were not routinely tested for EGFR and/or ALK receptor tyrosine kinase gene (ALK) mutations. However, of the patients who were tested, none harbored either mutation. Of the 25 patients with disease recurrence by the time of last follow-up, 11 received salvage therapy. Five patients received salvage chemotherapy. Three patients received salvage programmed cell death 1 inhibitors (nivolumab or pembrolizumab). Two patients received salvage thoracic radiotherapy. One patient received salvage tyrosine kinase inhibitor therapy (ponatinib).
Radiotherapy
The median prescribed radiation dose was 60 Gy (range 48-72). One patient was slated to receive 60 Gy but declined further therapy after the first 48 Gy (24 fractions). Two patients received a total of 72 Gy because they were enrolled on a prospective trial that consisted of 60 Gy of conventionally fractionated radiation followed by a 12-Gy boost (two fractions) to residual disease using stereotactic body radiotherapy (SBRT). Radiotherapy details are summarized in Table 2 . Table 2 .
GTV Volume Dynamics
We calculated GTV volume at fractions 1, 11, and 21 and at the last fraction. The median GTV volume at fraction 1 (GTV F1 ) was 77. 
DMFS
The 2-year DMFS rate for the entire group was 44.4% (95% CI: 24.2-62.9). The 2-year DMFS rate for patients with GTV F1-F21 /GTV F1 greater than the median (median 50.3%) was 63.5% (95% CI: 31-83.9) versus 28.6% (95% CI: 7.9-53.8) for those with GTV F1-F21 / GTV F1 lower than the median. Log-rank testing showed a statistically significant relationship between greater GTV F1-F21 /GTV F1 and improved DMFS (p ¼ 0.02 [ Fig. 2D]) . The relationship between GTV F11-F21 /GTV F11 and DMFS was not statistically significant (p ¼ 0.118 [ Fig. 3D]) . UVA indicated that greater GTV F1-F21 /GTV F1 correlated with better DMFS (hazard ratio [HR] ¼ 0.35, 95% CI: 0.13-0.94, p ¼ 0.038) ( Table 3 ). On MVA after adjustment for age, sex, smoking history, initial GTV volume, chemotherapy regimen, T stage, and N stage, there was a trend toward improved DMFS associated with higher GTV F1-F21 /GTV F1 (HR ¼ 0.32, 95% CI: 0.10-1.03, p ¼ 0.056) ( Table 4 ). There were no statistically significant associations detected between distant control and absolute tumor volume changes at any interval during treatment. 
PFS
The 2-year PFS rate was 37.4% (95% CI: 21.4-53.3) for the entire cohort. The 2-year PFS rates for patients with GTV F1-F21 /GTV F1 greater than the median (median ¼ 50.3%) were 47.1% (95% CI 9.4-49.8) versus 27.7% (95% CI: 22.6-68.4) for those with GTV F1-F21 /GTV F1 less than the median. Log-rank testing indicated that higher GTV F1-F21 /GTV F1 correlated with improved PFS (p ¼ 0.05) (Fig. 2B) . On MVA, this association remained significant (p ¼ 0.043 [see Table 4 ]). Log-rank testing also showed a significant association between higher GTV F11-F21 /GTV F11 and improved PFS (p ¼ 0.019) (Fig. 3B ). On MVA, there remained a correlation between higher GTV F11-F21 /GTV F11 and improved PFS (HR ¼ 0.39, 95% CI 0.16-0.96, p ¼ 0.04) (see Table 4 ). There were no significant associations detected between PFS and absolute tumor volume changes at any interval during treatment.
OS
The 2-year rate of OS was 53.9% (95% CI: 38-67.5) for the entire cohort. The 2-year OS for patients with GTV F1-F21 /GTV F1 greater than the median (median 50.3%) was 68.2% (95% CI: 43.8-83.8) versus 40.2% (95% CI: 20.2-59.5) for those with GTV F1-F21 /GTV F1 less than the median. Log-rank testing showed a statistically significant correlation between larger GTV F1--F21 /GTV F1 and improved OS (p ¼ 0.039) (Fig. 2A) . UVA detected a statistically significant association between higher GTV F1-F21 /GTV F1 and improved OS (HR ¼ 0.40, 95% CI: 0.16-0.98, p ¼ 0.046 [see Table 3 ]). On MVA, there was a trend toward significance between higher GTV F1-F21 /GTV F1 and improved OS (HR ¼ 0.36, 95% CI 0.12-1.07, p ¼ 0.067).
The 2-year OS for patients with GTV F11-F21 /GTV F11 greater than the median (median ¼ 22.8%) was 67.7% (95% CI 43.0 -83.5) versus 41.2% (95% CI: 21.2-60.2) for those with GTV F11-F21 /GTV F11 less than the median. There was a trend toward significance between higher GTV F11-F21 /GTV F11 and improved OS (p ¼ 0.058) (Fig. 3A) . After adjustment for covariates in MVA, higher GTV F11-F21 /GTV F11 was associated with improved OS (HR ¼ 0.31, 95% CI: 0.11-0.88, p ¼ 0.027) (see Table 4 ). There were no significant associations detected between OS and absolute tumor volume changes during treatment. 
Discussion
The standard of care for locally advanced unresectable NSCLC is concurrent definitive chemoradiation to doses of 60 to 66 Gy. With use of this strategy, however, outcomes remain poor, with a median PFS of 10 to 12 months, median OS of 20 to 28 months, and 2-year local recurrence rates of 30% to 40%. To date, the only published study correlating CBCT-based tumor volume changes with clinical outcomes was by Jabbour et al., who reported a median relative tumor volume reduction of 39.3% during treatment and a correlation between relative volume reduction and OS; interestingly, neither local nor distant control correlated with relative tumor volume reduction. 9 Our results show that kV-CBCT tumor volume dynamics did not correlate with LRC, defined as freedom from failure in the ipsilateral lung and/or mediastinum. However, greater relative volume changes during the first 4 weeks of treatment (>50%) were significantly associated with better distant control, PFS, and OS. Similarly, greater relative volume loss between fractions 11 and 21 was associated with improved PFS. These data are hypothesis generating, as they suggest that tumor volume changes on kV-CBCT can provide important prognostic information for patients undergoing definitive radiotherapy for LA-NSCLC. Perhaps early primary tumor response during treatment indicates the efficacy of concurrent chemotherapy in controlling microscopic metastatic disease. Alternatively, improved local control may translate into improved distant control by decreasing hematologic dissemination from local disease progression. Interestingly, absolute volume changes did not correlate with clinical outcomes at any time point during treatment, likely because of the wide range of initial tumor volumes. A third potential hypothesis is that larger tumor volume changes seen on kV-CBCT may serve as a radiographic marker for more favorable genetic and/or biologic profiles that result in improved disease control and OS. It is this population that would likely benefit most from reducing long-term toxicities associated with chemoradiation.
Adaptive radiotherapy allows practitioners to decrease target volumes on the basis of interval tumor volume reduction during treatment, potentially allowing for reduction of acute and long-term treatment related toxicities. The clinical utility of this strategy depends on the timing and magnitude of tumor volume changes during therapy. Much of the available data regarding tumor volume dynamics are limited to singleinstitutional experiences. 10, 11 The largest such experience, by Berkovic et al., analyzed weekly kV-CBCT images for 21 patients and reported an average relative GTV reduction during radiotherapy of 50.1%. They concluded that adaptive radiotherapy performed at approximately fraction 15 maximizes dosimetric benefits with regard to total lung dose. 12 Fox et al. similarly analyzed primary tumor dynamics on the basis of interval diagnostic CT scans after 30 Gy and 50 Gy of radiotherapy for 22 patients and report median relative GTV reductions of 24.7% and 44.3% at each time point, respectively. 13 Ramsey et al. utilized an adaptive radiotherapy technique for seven patients with NSCLC and were able to reduce GTV volumes by 60% to 80% and the ipsilateral lung percent volume receiving at least 20 Gy by 21% on average.
14 Additional efforts to apply adaptive planning and/or quantify interfractional tumor volume changes during conventional radiation have been limited to small numbers of patients with heterogeneous 18 Although adaptive radiation planning appears promising as a strategy to reduce normal tissue doses and risk of toxicity, it should be performed under prospective clinical trials, as shrinking treatment volumes could potentially lead to underdosing in cases of microscopic disease that is not covered by adaptive plans.
Our study is, to the best of our knowledge, the largest and most homogeneous of its kind to evaluate primary tumor dynamics during conventional radiotherapy for locally advanced NSCLC. We report median absolute and relative GTV volume decreases of 39.9 cm 3 and 62%, respectively, during treatment. Moreover, after just 2 weeks of treatment, 50% of our patients experienced greater than 30% relative tumor shrinkage, suggesting that there is a significant subset of patients who would benefit from adaptive replanning. In addition to these impressive primary tumor volume changes, it is likely that similar magnitudes of regional nodal shrinkage occur, further decreasing treatment volumes and sparing normal structures (lung, heart, esophagus, spinal cord, etc.). The fact that tumor volume loss is taking place so early in treatment is advantageous for adaptive planning, as it allows for earlier replanning with higher impact because of the larger proportion of fractions to be delivered to reduced treatment volumes.
Conclusions
Our findings suggest that relative tumor volume changes during the first 4 weeks of treatment may provide valuable prognostic information, including OS and PFS, for patients with stage III NSCLC treated with definitive chemoradiation. Additionally, tumor changes seen on kV-CBCT offer an opportunity for adaptive planning. Advantages of adaptive planning include smaller treatment fields, avoidance of normal tissue, and potential for safer dose escalation efforts. RTOG 1106 is an ongoing randomized phase II trial evaluating interval PET/CT-based adaptive radiotherapy after the initial 46.2 Gy, with a goal of dose escalation to 66 to 80.4 Gy while maintaining a mean lung dose less than 20 Gy. Our tumor dynamics data suggest that this strategy is justified and has the potential to improve local control for patients with locally advanced NSCLC. CI, confidence interval; GTV F1-F21 /GTV F1 , ratio or percent GTV volume change between fraction 1 and fraction 21 over GTV at fraction 1; GTV F1-F21 /GTV F1 , ratio or percent GTV volume change obtained by dividing volume changes between fraction 1 and fraction 21 by original tumor volume at fraction 1; GTV F11-F21 /GTV F11 , ratio or percent GTV volume changes obtained by dividing volume changes between fraction 11 and fraction 21 by tumor volume at fraction 1; HR, hazard ratio.
